Last edition
News about "CDSCO Approval"
CDSCO Approves AstraZeneca's Trastuzumab Deruxtecan Plus Pertuzumab Combination
AstraZeneca Pharma India has received CDSCO approval for trastuzumab deruxtecan plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
CDSCO Approval | 12/06/2026 | By News Bureau
Eli Lilly and Company Launches Lormalzi for Early-Stage Alzheimer's Treatment in India
Eli Lilly and Company India has launched Lormalzi, a once-monthly amyloid-targeting therapy approved for early-stage Alzheimer’s disease, marking a significant advancement in evidence-based treatment options for cognitive decline in India.
CDSCO Approval | 14/05/2026 | By News Bureau
AstraZeneca Secures CDSCO Approval for Breast Cancer Drug in India
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell and distribute its breast cancer therapy Datopotamab Deruxtecan in India.
CDSCO Approval | 20/12/2025 | By Darshana | 173
Lilly India Receives CDSCO Approval for Donanemab to Treat Early Alzheimer's Disease
Eli Lilly and Company (India) Pvt. Ltd. has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for donanemab, a treatment for adults in the early symptomatic stages of Alzheimer’s disease.
CDSCO Approval | 18/11/2025 | By Darshana | 491
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy